BETAUpdated 7 Sept 2026, 13:55

Beta Drugs Limited

BETAUpdated 7 Sept 2026, 13:55

Market Cap

₹2,339Cr.

Current Price

₹2,110

High / Low

₹2,808/990

Stock P/E

146

Book Value₹148

Dividend Yield0.00%

ROCE11.2%

ROE10.3%

Face Value₹10.0

About

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]

Quarterly results

Last reported quarters₹ Cr.

Profit & loss

Annual statement₹ Cr.

Shareholding pattern

As of Jun 2026%

Shareholding trend

Ownership over time%

Balance sheet

Assets & liabilities₹ Cr.

Cash flows

Operating, investing & financing₹ Cr.

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	112	61	92	104	109	117	96	92	101	93	81	87
Inventory Days	3,115	69	37	38	76	64	65	44	60	71	84	94
Days Payable	5,256	97	108	82	121	97	111	101	102	116	124	132
Cash Conversion Cycle	-2,029	33	21	60	64	84	49	34	59	48	41	49
Working Capital Days	-758	-19	17	50	62	65	81	63	83	72	68	74
ROCE %	-3%	22%	49%	29%	18%	17%	16%	27%	28%	27%	16%	11%

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 7 September 2026 at 13:55

BETA DRUGS LIMITED (BETA) financials — quarterly results, P&L, cash flow, balance sheet, shareholding